Summary – our clinical studies

Our clinical development program will provide us with a broad set of data and information about melflufen’s efficacy in various patient groups. We initiated preparations for an NDA submission based on t...

BRIDGE

SUPPORTING Ongoing phase 2 trial with up to 45 patients Open-label, single-arm study for patients with reduced renal function Positioning study to show melflufen’s treatment profile within this patient g...

ANCHOR

EXPLORATIVE Ongoing phase 1/2 study with up to 64 patients The patients have received 1–4 earlier lines of therapy including IMiDs and PIs Demonstrates how melflufen can be administered as a combination t...

OCEAN

CONFIRMATORY Ongoing phase 3 study with up to 450 patients, including RRMM patients who are refractory to lenalidomide Direct comparison with pomalidomide in patients treated with IMiDs and PIs, and who...

HORIZON

PIVOTAL STUDY Ongoing phase 2 study in 157 patients RRMM patients with few or no remaining treatment options Patients have received >2 earlier lines of therapy with IMiDs and PIs and are refractory...

O-12-M1

SUPPORTING Completed phase 2 clinical study with 45 patients Included RRMM patients who had received a median of 4 prior lines of therapy, and became refractory to lenalidomide (immunomodulatory pharmaceutical...